Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ASKE $$AFTER LUNCH LOADING SPECIAL$$ 0.0017
ASKE $$BOUNCE TIME$$ 0.0018
ASKE $$HUGE BID BUILDING
ASKE $$CHECK DAILY AND 5 MIN. CHARTS REVERSAL
ASKE $$TRUCKING NOW 0.0021
ASKE $$REVERSAL TAKING PLACE HEADING UP 0.0018 BY 0.0019
ASKE LOOKING GOOD 0.0017 0.0018
ASKE LOOKING GOOD 0.0017 0.0018
ASKE LOOKING GOOD 0.0017 0.0018
BFLX REVERSAL LOOKING GOOD
BFLX LOOKING GOOD
BIG MONEY COMING
GRBG $$LOOKING GOOD$$ LOAD EM UP
INHC $$$$$$ FOR 2-16 THURSDAY
INHC STANDS FOR IN HIGH COTTON
MFTH $1MILLION BUYBACK OF 10MM SHARES UP TO 10CENTS SHARE
MFTH HUGH STOCK BUYBACK NEWS
MFTH HUGH BUYBACK NEWS OUT
MFTH Medisafe 1 Technologies to Start the $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share
17 hours 56 minutes ago - PR Newswire via Comtex
Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company plans to start the implementation of the share buyback at the beginning of the forthcoming month of March 2012
Under the program approved by the BOD, Medisafe 1 Technologies is authorized to repurchase up to 10 million of its outstanding shares of common stock during the next 12 months at a price up to $0.10 per share on the open market or by conducting privately negotiated transactions depending on current market conditions and other factors.
"Medisafe 1 Technologies continues to progress in our efforts to bring further added value to our shareholders," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "The repurchase of shares will enable us to acquire additional technologies that augment our existing commercial product line and we will updating our shareholders in the forthcoming weeks of new and exciting news in regards to further acquisitions."
HWIC HARD TO GET SHARES
ATTD LOOKING GOOD AND NEWS OUT
ATTD BIG PLAY FOR TODAY WATCH AND SEE
MARKING BOARD I MISSED THIS ONE SOMEHOW BUT I FOUND IT NOW
GOOD JOB RUSTLER I JUST GIVE A PERSON MARK
GREAT INTERVIEW GIDDY UP ATTD
IF WE HOLD COULD BE WORTH MILLIONS BRAVO HE SAID BOUGHT AT .14 WENT TO 1.40
DON'T GIVE THEM YOUR SHARES CHEAP MAKE THEM PAY FOR THEM
ATTD ALL ABOARD
ATTD Attitude Drinks Reports Sales Agreement with Walgreens
10 hours 32 minutes ago - Close-Up Media via Comtex
Attitude Drinks, a brand beverage development company and creator of the Phase III Recovery brand, announced a sales agreement with Walgreens.
In a release, Roy Warren, CEO of Attitude Drinks said, "The introduction of Phase III into the authorized Walgreens locations throughout the state of Florida is a great indicator of brand growth and reception within the beverage community. The selling of Phase III into these Walgreens stores, a chain recognized as one of the strongest drug and convenience stores in the country, is exciting and flattering. We intend to support this fantastic new relationship in raising the sales to their fullest potential."
"We are excited about the authorization of Phase III Recovery in the Florida Division of Walgreens. It is clear that Florida consumers are looking to purchase Phase III and now that it is available in Walgreens--problem solved," said Jack Shea, Executive Vice President of Sales for Attitude.
The Company noted the brand will be distributed to Walgreens stores throughout the majority of the state. This represents over 800 stores within the chain. Walgreens, a company built around the concept of one stop shopping, has now increased their focus into the health and wellness arena.
Walgreens is a drugstore chain.$$$
ATTD LOOKING GOOD TO ME
ATTD LOOKING GOOD TODAY
Looking Good Today I'm in
CBIS Cancer Patient Success Prompts Cannabis Science To Begin FDA Investigational New Drug (IND) Application Process
1 days 10 minutes ago - BusinessWire via Comtex
Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to inform that the current progress and success with their numerous self-medicated cancer patients, has lead the Company to immediately begin the Investigational New Drug (IND) application process that will target cancer treatment.
Cannabis Science is currently tracking numerous cancer patients, who are self-medicating with cannabis extracts. The Company has evident success with these patients, which creates support to submit an IND application to the FDA. The prescription pharmaceutical market is the number one target market for Cannabis Science, and with having the appropriate backup for the application process, it is all very promising for the Company and cancer patients worldwide.
Cannabis Science currently has documented images for the first three apparently successful self-medicated cancer patients, and the Company is waiting for more documentation and images associated with other patients. The first patient had basal cell carcinoma (skin cancer) on her face, and after applying the topical cannabis extracts within 10 days it appeared the lesion was gone. Cannabis Science received documentation from her surgeon that she would not need to undergo any surgical procedures and was free of cancer cells. The second patient, who has basal cell carcinoma on their arm, has gotten dramatic results. Their treatment has been completed, and Cannabis Science is just waiting for a full biopsy report from the patient's physician to inform that they are free of cancer cells. A special case, involves a third patient with severe squamous cell carcinoma on his head. His physician prior to using cannabis extracts had told this patient, that there was nothing more that could be done. Cannabis Science has gotten drastic results, along with photographed documentation of the treatment process. This patient's treatment is still in progress, but with photographic evidence you can see the effectiveness of the cannabis-based extracts.
You can view the photos and information of these patients on the Cannabis Science website www.cannabisscience.com, click the button "Breaking News" and you will find the associated news releases of each patient. You can also view each different patient's documentation and images by clicking the buttons, "View Images of 1st Self-Medicated Patient & The Apparent Success", "View Images of 2nd Self-Medicated Patient & The Apparent Success", and "View Images of 3rd Self-Medicated Patient & His Apparent Success".
Cannabis Science is in an excellent position to begin the FDA process for prescription cancer medications. Cannabis Science is seeing even more success with other self-medicated cancer patients, and will get updated reports on them as well. All of the positive outcomes from the patients create a suitable foundation to enter the FDA market of prescription drugs.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance
IS
CBIS Cancer Patient Success Prompts Cannabis Science To Begin FDA Investigational New Drug (IND) Application Process
1 days 10 minutes ago - BusinessWire via Comtex
Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to inform that the current progress and success with their numerous self-medicated cancer patients, has lead the Company to immediately begin the Investigational New Drug (IND) application process that will target cancer treatment.
Cannabis Science is currently tracking numerous cancer patients, who are self-medicating with cannabis extracts. The Company has evident success with these patients, which creates support to submit an IND application to the FDA. The prescription pharmaceutical market is the number one target market for Cannabis Science, and with having the appropriate backup for the application process, it is all very promising for the Company and cancer patients worldwide.
Cannabis Science currently has documented images for the first three apparently successful self-medicated cancer patients, and the Company is waiting for more documentation and images associated with other patients. The first patient had basal cell carcinoma (skin cancer) on her face, and after applying the topical cannabis extracts within 10 days it appeared the lesion was gone. Cannabis Science received documentation from her surgeon that she would not need to undergo any surgical procedures and was free of cancer cells. The second patient, who has basal cell carcinoma on their arm, has gotten dramatic results. Their treatment has been completed, and Cannabis Science is just waiting for a full biopsy report from the patient's physician to inform that they are free of cancer cells. A special case, involves a third patient with severe squamous cell carcinoma on his head. His physician prior to using cannabis extracts had told this patient, that there was nothing more that could be done. Cannabis Science has gotten drastic results, along with photographed documentation of the treatment process. This patient's treatment is still in progress, but with photographic evidence you can see the effectiveness of the cannabis-based extracts.
You can view the photos and information of these patients on the Cannabis Science website www.cannabisscience.com, click the button "Breaking News" and you will find the associated news releases of each patient. You can also view each different patient's documentation and images by clicking the buttons, "View Images of 1st Self-Medicated Patient & The Apparent Success", "View Images of 2nd Self-Medicated Patient & The Apparent Success", and "View Images of 3rd Self-Medicated Patient & His Apparent Success".
Cannabis Science is in an excellent position to begin the FDA process for prescription cancer medications. Cannabis Science is seeing even more success with other self-medicated cancer patients, and will get updated reports on them as well. All of the positive outcomes from the patients create a suitable foundation to enter the FDA market of prescription drugs.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance
I JUST MARKED U HOTSTOCKACE 1940 LOOKS GOOD
SAPX GOING BACK UP TOMORROW
THANKS INFINITY BAGGER I MARKED U AND BOARD AND FOX AND SIGNED UP FOR EMAIL
SAPX RUNNER FOR MONDAY
LOOKING GOOD I'M IN
GRNE GRNE Reports Salon Revenues Top $2.8 Million in 2011
1 days 2 hours 28 minutes ago - Marketwire
Green Endeavors, Inc. (OTCQB: GRNE) (PINKSHEETS: GRNE), a majority owned subsidiary of Nexia Holdings, Inc. (PINKSHEETS: NXHD), announces revenue figures for year end December 31, 2011. Combined unaudited revenues for both salon locations were $2,820,870 for the year end December 31, 2011; which is an increase of $658,400 or 30% from the comparable year end of 2010. Our Marmalade location reported year end sales for 2011 of $753,238; a $598,080 increase over the year end of 2010 which reported only three full months of operations. Our Liberty Heights (flagship) location also is reporting revenue growth with year end 2011 sales of $2,067,633; a $60,321 or 3% increase compared to year end revenues for 2010.